OPKO Health (NASDAQ:OPK) Shares Gap Down to $1.23

Shares of OPKO Health, Inc. (NASDAQ:OPK) gapped down prior to trading on Friday . The stock had previously closed at $1.23, but opened at $1.20. OPKO Health shares last traded at $1.24, with a volume of 321,622 shares traded.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on OPK. Barrington Research reissued an “outperform” rating and issued a $1.50 price target on shares of OPKO Health in a research report on Monday, April 1st. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, April 3rd. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Finally, Piper Sandler reissued an “overweight” rating and issued a $5.00 price target on shares of OPKO Health in a research report on Monday, April 1st.

OPKO Health Stock Performance

The stock’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.24. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $181.90 million for the quarter, compared to analyst estimates of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. OPKO Health’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) EPS. Research analysts expect that OPKO Health, Inc. will post -0.33 EPS for the current year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $0.87 per share, with a total value of $435,000.00. Following the purchase, the chief executive officer now directly owns 210,968,225 shares in the company, valued at $183,542,355.75. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $0.87 per share, with a total value of $435,000.00. Following the purchase, the chief executive officer now directly owns 210,968,225 shares in the company, valued at $183,542,355.75. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard M. Krasno purchased 30,000 shares of the business’s stock in a transaction on Monday, January 29th. The stock was bought at an average cost of $0.99 per share, with a total value of $29,700.00. Following the purchase, the director now owns 103,333 shares in the company, valued at $102,299.67. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 4,630,000 shares of company stock valued at $4,422,700. Company insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

Institutional investors have recently made changes to their positions in the business. IPG Investment Advisors LLC purchased a new stake in shares of OPKO Health in the 4th quarter valued at $30,000. Verition Fund Management LLC purchased a new stake in shares of OPKO Health in the 2nd quarter valued at $36,000. River Wealth Advisors LLC purchased a new stake in shares of OPKO Health in the 3rd quarter valued at $38,000. Guggenheim Capital LLC purchased a new stake in shares of OPKO Health in the 1st quarter valued at $38,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of OPKO Health in the 1st quarter valued at $39,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.